Monica Gandhi, MD, MPH

Headshot of Monica Gandhi
User Profile Photo

Monica Gandhi, MD, MPH

User Profile Name
Director, UCSF-Bay Area CFAR
Professor, School of Medicine
User Profile Title
User Profile Email

Biography

Dr. Gandhi has been at UCSF since 1996 when she came here for her medical residency after attending Harvard Medical School. She completed an ID fellowship at UCSF from 1999-2003 and a Masters’ in Public Health in Epidemiology/Biostatistics from the University of California, Berkeley in 2001, as well as a Traineeship in AIDS Prevention Studies (TAPS) post-doctoral fellowship. She has been an NIH funded researcher since 2003, first with a K23 award and now with multiple R01 and R21 grants to help run the UCSF Hair Analytical Laboratory (HAL), a laboratory that focuses on objective adherence metrics to HIV treatment and prevention for multiple UCSF-based and global investigators in hair and urine. She served on the Office of AIDS Research Advisory Committee (OARAC) from 2014-2017 and Chair from 2017-2018. She also serves on the ACTG Executive Committee. She has served as the co-director of the CFAR Mentoring Program for the past five years and has a dedicated interest in HIV mentorship and education.

Dr. Gandhi serves as the Medical Director of the Ward 86 HIV Clinic (since January 2014) and won the HIV Medical Association (HIVMA) Clinical Educator Award in 2017 and was awarded the Master Clinician award in the Department of Medicine in 2019. Beyond an interest in adherence metrics and PrEP, Dr. Gandhi has a special interest in HIV and women and sex differences in HIV medicine. She is thrilled to serve in this role to support the HIV/AIDS researcher community across UCSF and our many affiliates. She is especially interested in mentoring early stage investigators, especially those from underrepresented racial/ethnic minorities, from disadvantaged backgrounds, and with disabilities. Monica plans an open door policy with the CFAR community here at UCSF and is excited to serve with you all in continuing to make UCSF an innovative and exciting place to conduct HIV research.

User Profile Bio

Displaying 126 - 150 of 291

  1. Hill LM, Golin CE, Pack A, Carda-Auten J, Wallace DD, Cherkur S, Farel CE, Rosen EP, Gandhi M, Asher Prince HM, Kashuba ADM. Using Real-Time Adherence Feedback to Enhance Communication About Adherence to Antiretroviral Therapy: Patient and Clinician Perspectives. J Assoc Nurses AIDS Care. 2020 Jan-Feb; 31(1):25-34.
  2. Carrico AW, Neilands TB, Dilworth SE, Evans JL, G?mez W, Jain JP, Gandhi M, Shoptaw S, Horvath KJ, Coffin L, Discepola MV, Andrews R, Woods WJ, Feaster DJ, Moskowitz JT. Randomized controlled trial of a positive affect intervention to reduce HIV viral load among sexual minority men who use methamphetamine. J Int AIDS Soc. 2019 12; 22(12):e25436.
  3. Scott HM, Spinelli M, Vittinghoff E, Morehead-Gee A, Hirozawa A, James C, Hammer H, Liu A, Gandhi M, Buchbinder S. Racial/ethnic and HIV risk category disparities in preexposure prophylaxis discontinuation among patients in publicly funded primary care clinics. AIDS. 2019 11 15; 33(14):2189-2195.
  4. Fulcher JA, Li F, Cook RR, Zabih S, Louie A, Okochi H, Tobin NH, Gandhi M, Shoptaw S, Gorbach PM, Aldrovandi GM. Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis. Open Forum Infect Dis. 2019 Nov; 6(11):ofz463.
  5. Velloza J, Bacchetti P, Hendrix CW, Murnane P, Hughes JP, Li M, Curlin ME, Holtz TH, Mannheimer S, Marzinke MA, Amico KR, Liu A, Piwowar-Manning E, Eshleman SH, Dye BJ, Gandhi M, Grant RM, HPTN 067/ADAPT Study Team . Short- and Long-Term Pharmacologic Measures of HIV Pre-exposure Prophylaxis Use Among High-Risk Men Who Have Sex With Men in HPTN 067/ADAPT. J Acquir Immune Defic Syndr. 2019 10 01; 82(2):149-158.
  6. Velloza J, Bacchetti P, Hendrix CW, Murnane P, Hughes JP, Li M, Curlin ME, Holtz TH, Mannheimer S, Marzinke MA, Amico KR, Liu A, Piwowar-Manning E, Eshleman SH, Dye BJ, Gandhi M, Grant RM. Short- and Long-Term Pharmacologic Measures of HIV Pre-exposure Prophylaxis Use Among High-Risk Men Who Have Sex With Men in HPTN 067/ADAPT. J Acquir Immune Defic Syndr. 2019 10 01; 82(2):149-158.
  7. Gandhi M, Smeaton LM, Vernon C, Scully EP, Gianella S, Poongulali S, Sheth AN, Van Schalkwyk M, Klingman KL, Short WR, Opollo VS, Cohn SE, Scarsi KK, Firnhaber C, Bares S, Swaminathan S, Mngqibisa R, Connick E. Low Rate of Sex-specific Analyses in Presentations at the Conference on Retroviruses and Opportunistic Infections (CROI) Meeting, 2018: Room to Improve. J Acquir Immune Defic Syndr. 2019 Aug 15; 81(5):e158-e160.
  8. Murnane PM, Bacchetti P, Currier JS, Brummel S, Okochi H, Phung N, Louie A, Kuncze K, Hoffman RM, Nematadzira T, Soko DK, Owor M, Saidi F, Flynn PM, Fowler MG, Gandhi M. Tenofovir concentrations in hair strongly predict virologic suppression in breastfeeding women. AIDS. 2019 08 01; 33(10):1657-1662.
  9. Drain PK, Kubiak RW, Siriprakaisil O, Klinbuayaem V, Quame-Amaglo J, Sukrakanchana PO, Tanasri S, Punyati P, Sirirungsi W, Cressey R, Bacchetti P, Okochi H, Baeten JM, Gandhi M, Cressey TR. Urine Tenofovir Concentrations Correlate with Plasma and Relates to TDF Adherence: A Randomized Directly-observed Pharmacokinetic Trial (TARGET Study). Clin Infect Dis. 2019 07 17.
  10. Spinelli MA, Glidden DV, Anderson PL, Gandhi M, McMahan VM, Defechereux P, Schechter M, Veloso VG, Chariyalertsak S, Guanira JV, Bekker LG, Buchbinder SP, Grant RM. Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project. AIDS Res Hum Retroviruses. 2019 09; 35(9):788-793.
  11. Spinelli MA, Glidden DV, Anderson PL, Gandhi M, Cohen S, Vittinghoff E, Coleman ME, Scott H, Bacon O, Elion R, Kolber MA, Buchbinder SP, Liu AY. Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing. J Acquir Immune Defic Syndr. 2019 06 01; 81(2):158-162.
  12. Mira Wang, Josh Miller, Shalean Collins, Marianne Santoso, Pauline Wekesa, Maricianah Onono, Monica Gandhi, Sera Young. Increased Social Support Mitigates the Negative Impact of Food Insecurity on Antiretroviral Adherence Among Postpartum Women in Western Kenya (P04-126-19). Current Developments in Nutrition. 2019 Jun 1; 3(Supplement_1).
  13. Paul Drain, Kenneth Ngure, Nelly Mugo, Matthew Spinelli, Purba Chatterjee, Peter Bacchetti, David Glidden, Jared Baeten, Monica Gandhi. Testing a Real-Time Tenofovir Urine Adherence Assay for Monitoring and Providing Feedback to PrEP in Kenya (the PUMA study): A Pilot Randomized Clinical Trial (Preprint). JMIR Research Protocols. 2019 Jun 13.
  14. Tram KH, Mwangwa F, Chamie G, Atukunda M, Owaraganise A, Ayieko J, Jain V, Clark TD, Kwarisiima D, Petersen ML, Kamya MR, Charlebois ED, Havlir DV, Marquez C, SEARCH collaboration . Predictors of isoniazid preventive therapy completion among HIV-infected patients receiving differentiated and non-differentiated HIV care in rural Uganda. AIDS Care. 2020 01; 32(1):119-127.
  15. Mira Wang, Josh Miller, Shalean Collins, Marianne Santoso, Pauline Wekesa, Maricianah Onono, Monica Gandhi, Sera Young. Increased Social Support Mitigates the Negative Impact of Food Insecurity on Antiretroviral Adherence Among Postpartum Women in Western Kenya (P04-126-19). Current Developments in Nutrition. 2019 Jun 1; 3(Supplement_1).
  16. Camlin CS, Akullian A, Neilands TB, Getahun M, Bershteyn A, Ssali S, Geng E, Gandhi M, Cohen CR, Maeri I, Eyul P, Petersen ML, Havlir DV, Kamya MR, Bukusi EA, Charlebois ED. Gendered dimensions of population mobility associated with HIV across three epidemics in rural Eastern Africa. Health Place. 2019 05; 57:339-351.
  17. Hojilla JC, Satre DD, Glidden DV, McMahan VM, Gandhi M, Defechereux P, Guanira JV, Mehrotra M, Grant RM, Carrico AW. Brief Report: Cocaine Use and Pre-exposure Prophylaxis: Adherence, Care Engagement, and Kidney Function. J Acquir Immune Defic Syndr. 2019 05 01; 81(1):78-82.
  18. Teeraananchai S, Kerr SJ, Gandhi M, Do VC, Van Nguyen L, Tran DNH, Kosalaraksa P, Singtoroj T, Thammajaruk N, Jupimai T, Sohn AH. Determinants of Viral Resuppression or Persistent Virologic Failure After Initial Failure With Second-Line Antiretroviral Treatment Among Asian Children and Adolescents With HIV. J Pediatric Infect Dis Soc. 2019 May 24.
  19. Sharma A, Stephenson R, Sallabank G, Merrill L, Sullivan S, Gandhi M. Acceptability and Feasibility of Self-Collecting Biological Specimens for HIV, Sexually Transmitted Infection, and Adherence Testing Among High-Risk Populations (Project Caboodle!): Protocol for an Exploratory Mixed-Methods Study. JMIR Res Protoc. 2019 May 02; 8(5):e13647.
  20. Hojilla JC, Satre DD, Glidden DV, McMahan VM, Gandhi M, Defechereux P, Guanira JV, Mehrotra M, Grant RM, Carrico AW. Brief Report: Cocaine Use and Pre-exposure Prophylaxis: Adherence, Care Engagement, and Kidney Function. J Acquir Immune Defic Syndr. 2019 05 01; 81(1):78-82.
  21. Spinelli MA, Glidden DV, Rodrigues WC, Wang G, Vincent M, Okochi H, Kuncze K, Mehrotra M, Defechereux P, Buchbinder SP, Grant RM, Gandhi M. Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration project. AIDS. 2019 04 01; 33(5):867-872.
  22. M. Peluso, P. Burbelo, S. Kumar, S. Munter, R. Hoh, S. Lee, P. Hunt, R. Rutishauser, T. Henrich, S. Deeks. OP 4.2 Characterising ‘exceptional’ control among HIV elite controllers. Journal of virus eradication. 2019 Dec 1; 5:31.
  23. Clemenzi-Allen A, Neuhaus J, Geng E, Sachdev D, Buchbinder S, Havlir D, Gandhi M, Christopoulos K. Housing Instability Results in Increased Acute Care Utilization in an Urban HIV Clinic Cohort. Open Forum Infect Dis. 2019 May; 6(5):ofz148.
  24. Scully EP, Gandhi M, Johnston R, Hoh R, Lockhart A, Dobrowolski C, Pagliuzza A, Milush JM, Baker CA, Girling V, Ellefson A, Gorelick R, Lifson J, Altfeld M, Alter G, Cedars M, Solomon A, Lewin SR, Karn J, Chomont N, Bacchetti P, Deeks SG. Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation. J Infect Dis. 2019 03 15; 219(7):1084-1094.
  25. Coffey S, Bacchetti P, Sachdev D, Bacon O, Jones D, Ospina-Norvell C, Torres S, Lynch E, Camp C, Mercer-Slomoff R, Lee S, Christopoulos K, Pilcher C, Hsu L, Jin C, Scheer S, Havlir D, Gandhi M. RAPID antiretroviral therapy: high virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic population. AIDS. 2019 04 01; 33(5):825-832.